PCA-Index: The combination of serum levels of p53 and CA125 for breast cancer early detection
Laboratory Medicine · 2025
DOI: 10.1093/labmed/lmaf032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laboratory Medicine, 2025. Verfasst von Mohamed El-Far und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Suppressor Protein p53, CA-125 Antigen, Early Detection of Cancer. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Introduction
Early-stage diagnosis is crucial for the best prognosis in breast cancer. Here, our objective was to compare serum tumor protein p53 (TP53) levels in an Egyptian population with benign breast disease vs breast cancer to investigate the protein’s utility in early detection and intervention, alongside existing tumor-related markers, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and CA15.3.
Methods
We enrolled 231 patients in this study: 146 with breast cancer, 50 with benign conditions, and 35 without breast pathology (healthy control individuals). The serum level of TP53, CEA, CA125, and CA15.3 was quantitated using an enzyme-linked immunosorbent assay. Data were examined using the t test, Spearman correlation, and receiver operating characteristic curve analysis.
Results
Patients with breast cancer showed clinically significant higher serum levels of TP53 than did individuals with benign conditions and healthy control individuals. Elevated TP53 levels were correlated with advanced tumor stage (P <.001) and high-tumor grade (P <.001). TP53 effectively distinguished between benign disease and early-stage breast cancer, with an area under the curve of 0.88, 73.6% sensitivity, and 78.0% specificity. Multinomial logistic regression analysis showed that combining TP53 with other tumor-related markers improved early breast cancer detection. Both TP53 and CA125 remained significant predictors in this analysis. A new function, the PCA-Index, which combines concentrations of TP53 and CA125, was developed to enhance early detection in early stages (T1-T2) and low grades (1-2) with notable results: areas under the curve of 0.96 and 0.98, a specificity of 90.0%, and sensitivities of 85.7% and 91.7%, respectively.
Discussion
The combined detection of TP53 and CA125, the PCA-Index, has important clinical value for early detection of breast cancer with a high degree of sensitivity and specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt.
- Research and Development Department, Biotechnology Research Center, New Damietta, Egypt.
- Surgical Oncology Department, Mansoura Oncology Centre, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- Biochemistry Division, Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt.
Zitieren
APA
El-Far, M., Abdelhady, M. R., Abouzid, A., Omran, M. M., & Attallah, A. M. (2025). PCA-Index: The combination of serum levels of p53 and CA125 for breast cancer early detection. Laboratory Medicine. https://doi.org/10.1093/labmed/lmaf032
Vancouver
El-Far M, Abdelhady MR, Abouzid A, Omran MM, Attallah AM. PCA-Index: The combination of serum levels of p53 and CA125 for breast cancer early detection. Laboratory Medicine. 2025. doi:10.1093/labmed/lmaf032
BibTeX
@article{ElFar2025,
author = {El-Far, Mohamed and Abdelhady, Mohamed R and Abouzid, Amr and Omran, Mohamed M and Attallah, Abdelfattah M},
title = {PCA-Index: The combination of serum levels of p53 and CA125 for breast cancer early detection},
journal = {Laboratory Medicine},
year = {2025},
doi = {10.1093/labmed/lmaf032}
}
EUVIMED